A cellular signature seen in the blood of multiple sclerosis patients may help determine their likelihood of relapse, potentially influencing which therapy physicians prescribe, a study found. Philip De Jager, HMS associate professor of neurology at Brigham and Women’s Hospital, is an author of the study.
